Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
AEZS PDUFA 11-5 http://stockcharts.com/h-sc/ui?s=AEZS
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=101482458&txt2find=aezs
took small starter in this yesterday at 1.07. Sold out a few months ago got in way to early. Still early and chance of dilution but as tradetomuch points out this could run easily.
ANAC 7-29 PDUFA (14.71) http://stockcharts.com/h-sc/ui?s=ANAC
ACRX PDUFA 7-27 (9.16) http://stockcharts.com/h-sc/ui?s=acrx
HALO ADCOM 7-31 (7.96) http://stockcharts.com/h-sc/ui?s=halo
SPPI PDUFA 8-9 (7.41) http://stockcharts.com/h-sc/ui?s=SPPI
ETRM (1.91) ADCOM 6-17 stockcharts.com/h-sc/ui?s=etrm
MACK ( 7.52 ) phase 2 data breast cancer drug end
http://stockcharts.com/h-sc/ui?s=mack
XOMA (4.05) phase 3 news June or July??
http://stockcharts.com/h-sc/ui?s=xoma
ANTH(2.98) phase 3 update due mid 2014
http://stockcharts.com/h-sc/ui?s=anth
ACST (.87) phase 2 results by end of 2nd qtr
http://stockcharts.com/h-sc/ui?s=acst
EGRX 7-6 PDUFA watch for $heff to start a position soon. Looking to get in this week possibly.
HRTX late june/early July resubmission of nda after CRL last year under old ticker. Has uplisted and changed ticker/brought in some new key management. Had some issues with manufacturer I believe that delayed their response to Crl. Had a r/s to get uplisted. AT or about R/s levels now.
NPSP 6-28-14 SNDA (supplementary new drug applications)
VTUS meeting with FDA 6-19-14
NKTR Adcom 6-11-14
OREX PDUFA 6-10-14
BDSI pdufa 6-7-14
trlpf pdufa 5-28
started board to share catalyst plays:
http://investorshub.advfn.com/boards/chair_board.asp?board_id=25924
If adding new catalyst to board type all bold.
OT created board to remember identify Bio Catalysts
http://investorshub.advfn.com/Bio-Tech-Catalyst-Plays-25924/
by putting all catalysts in bold print should be fast to find potential plays.
Navb snda 6-16
PGNX adcom 6-11
MNKD pdufa 7-15-14
Aezs. Presenting at asco. Pdufa long ways away.
Aeterna Zentaris: Poster to be Presented on the Design of Current ZoptEC Phase 3 Trial in Endometrial Cancer with Zoptarelin Doxorubicin at ASCO
By PR Newswire, May 22, 2014, 07:30:00 AM EDT
QUÉBEC CITY, May 22, 2014 /PRNewswire/ -
Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the "Company") today announced that a poster will be presented on the design of its current ZoptEC (Zoptarelin doxorubicin in Endometrial Cancer) Phase 3 trial in women with advanced, recurrent or metastatic endometrial cancer. The poster will be presented by lead investigator, David S. Miller MD, of the University of Texas Southwestern Medical Center in Dallas, during the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), to be held May 30-June 4, 2014 in Chicago. There are currently over 100 sites in operation and over 150 patients have been recruited for this ZoptEC Phase 3 trial.
Abstract TPS5630: "ZoptEC: Phase 3 study of zoptarelin doxorubicin (AEZS-108) in platinum-taxane pretreated endometrial cancer (Study AEZS-108-050)", David S. Miller, Hani Gabra, Guenter Emons, D. Scott McMeekin, Amit M. Oza, Sarah Madhu Temkin, Ignace Vergote.
Presenter: Dr. David S. Miller
Poster Session: Gynecologic Cancer
Date & Time: Saturday, May 31, 2014, 8:00 am - 11:45 am (Central time)
Venue: SHall A2, McCormick Place, Chicago
About Zoptarelin Doxorubicin
Zoptarelin doxorubicin represents a new targeting concept in oncology using a hybrid molecule composed of a synthetic peptide carrier and a well-known chemotherapy agent, doxorubicin. Zoptarelin doxorubicin is the first intravenous drug in advanced clinical development that directs the chemotherapy agent specifically to LHRH-receptor expressing tumors, resulting in a more targeted treatment with less damage to healthy tissue. The Company is currently conducting a Phase 3 trial in endometrial cancer under a Special Protocol Assessment, while zoptarelin doxorubicin is also in an investigator-initiated Phase 2 trial in prostate cancer. Aeterna Zentaris owns the worldwide rights to this compound.
About Aeterna Zentaris Inc.
Aeterna Zentaris is a specialty biopharmaceutical company engaged in developing novel treatments in oncology and endocrinology. The Company's pipeline encompasses compounds at various stages of development. For more information, visit www.aezsinc.com.
SOURCE Aeterna Zentaris Inc.
Read more: http://www.nasdaq.com/press-release/aeterna-zentaris-poster-to-be-presented-on-the-design-of-current-zoptec-phase-3-trial-in-20140522-00239#ixzz32RZxv0Eo
Thanks everyone! I think i hit everyone back.
I you have options that expire worthless is this considered a tax loss to offset short term profits from sales of stock?
Insv after getting vote for r.s out of way this should move in late summer leading up to nda
http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9NTQxMDAxfENoaWxkSUQ9MjMxMDE2fFR5cGU9MQ==&t=1
etrm I am somewhat surprised that the possiblity of dilution is not having an affect on price today.
lxrx I was in this earlier this year with you and lost a little. May revisit.
Sheff?@SheffStation Tweets·May 21
$LXRX catalyst is it plans to meet w/ FDA to discuss the potential advancement of LX4211 into Ph 3 dvlpmt for type 1 diabetes...on watch!
hoping that with drtx pdufa out of way and ETRM possibly diluting that money moves into PGNX and we start our run. Really think this has the potential to move next week.
ETRM sold out premarket today. Dilution before adcom.
vtus whoops dang ipad
Vagus think this a safe bottom play here too. I was going to avg down a little but jumped back into navb instead with a starter.
Etrm I need about .20 more to be in the green. I've had too much dead money in this stock for the last few months. Now if only Pgnx could get rolling
Vtus. I should have sold p.m this am. Think it will bounce back to 1.00 and I'm running. (That's the plan anyway). Still has a solid catalyst so no reason for it to stay at this price.
$heff out etrm+ pgnx. Not sure if this will slow the momentum o these plays.
ETRM. 2.30 would be 25% gain from these levels. Easily obtainable in next few weeks seeing it was 2.60 just a few months ago and a concrete catalyst just weeks away.
2.30 would be 25% gain from these levels. Easily obtainable in next few weeks seeing it was 2.60 just a few months ago and a concrete catalyst just weeks away.
Meeting with FDA quickly approaching. Followed $ heff into this one.